Robigo Bio has closed a Series A financing round led by Leaps by Bayer, with participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8, to commercialize engineered microbial seed treatments the company says can match synthetic crop chemistry at half the cost.

Financial terms were not disclosed. The Cambridge, Massachusetts-based company will deploy capital against two product launches and a broader push into broad-acre soil-borne pathogens, a market it sizes at $10 billion.

The first product, an engineered microbial seed treatment for soybean Sudden Death Syndrome, is scheduled for commercial launch in 2028. A second product targeting fusarium wilt in lettuce and berries follows in 2029. Early field data reviewed by the company showed the soybean treatment on track to match commercially available chemistries at half the cost — a benchmark with real money behind it, given that SDS drives an estimated $200 million to $500 million in annual losses for U.S. soybean growers. The specialty-crop fusarium wilt product delivered a 3x yield increase over untreated controls in company trials.

What does Robigo's microbial approach change?

Founder and CEO Dr. Andee Wallace drew a sharp line between her platform and the bulk of the biologicals market. "Growers shouldn't have to choose between a product that works and one that's affordable or sustainable," Wallace said. "If you go out and talk with growers, you know what they want: something that's simple that works with what they're doing today."

Nearly every commercial microbial product on the market uses wild-type organisms — naturally occurring strains selected for a useful trait. Robigo's process inverts that model. It selects microbes for shelf stability and manufacturing economics, then engineers in new traits computationally, including both the active bioingredients and safety parameters.

"We identify microbes that serve as a really solid foundation to build high-performing products on top of — they have the shelf stability, they have the manufacturing capabilities to be cost-effective — and then we engineer in these new traits that allow us to be much higher performing than what biologicals are doing today," Wallace said. She called it "an entirely different way to develop microbial and biological products from what's been historically done."

How does the platform compress development timelines?

Robigo's proprietary ARGO platform ties together microbial strain engineering, strain selection, and computational design of the bioactive compounds the microbes produce. The company claims ARGO can move a new biological product from design to field-tested in under 20 months. The industry norm, by comparison, runs three to five years.

The startup's first field trials last year cleared USDA and EPA review — what Wallace described as a regulatory first for a living engineered microbe expressing new traits in the field. The treatments are applied as a one-time seed treatment and continuously deliver active ingredients through the season with no change to grower workflows. Critically, the formulations do not require cold-chain storage, a logistical bottleneck that has long weighed on ag biologicals.

What does Leaps by Bayer see in the bet?

The Series A extends a multi-year relationship between Robigo and Leaps, Bayer's venture arm. Dr. Juergen Eckhardt, EVP and head of Leaps by Bayer, framed the investment as a platform play rather than a single-asset bet. "They are not just developing a single product but rather building an engine that can rapidly address diverse soil-borne pathogens across broadacre crops," Eckhardt said in a statement.

Robigo closed its seed round at the end of 2022, in early 2023. Wallace acknowledged the difficulty of the current fundraising climate but credited field data with closing the round. The Series A will also underwrite continued registration work; Robigo has already initiated the regulatory process for the soybean seed treatment, a step Wallace flagged as significant for an engineered-organism category still defining its own regulatory path.

What comes next for the soybean launch?

The 2028 commercial target now hinges on regulatory clearance, scaled manufacturing of the engineered strains, and grower-trials large enough to validate the half-cost chemistry match under commercial conditions. Robigo will need to convert its 20-month design-to-field cadence into a repeatable registration pipeline if it intends to treat the $10 billion broad-acre soil-borne pathogen market as more than a slide in a pitch deck.